After the published statement of the German Cardiac Society in March 2020, we continued and initiated guideline-recommended HF therapy in every patient with impaired LV- and/or RV-function as well as elevated NT pro-BNP plasma levels. This evidence concerns the gene NPPB and hydrops fetalis.